The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
The Distinctive Nature of HER2-Positive Breast Cancers
Burstein, H. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058197 · Cited by 541
Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction
Chasman, D. I. (2004) · JAMA · doi:10.1001/jama.291.23.2821 · Cited by 453
Belli, F., Testori, A., Rivoltini, L., Maio, M., Andreola, G., Sertoli, M. R., Gallino, G., Piris, A., Cattelan, A., Lazzari, I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.134 · Cited by 387
Longer Patents for Increased Generic Competition in the US
Grabowski, H. G., & Vernon, J. (1996) · PharmacoEconomics · doi:10.2165/00019053-199600102-00017 · Cited by 140
New estimates of drug development costs
Frank, R. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(03)00002-x · Cited by 126
Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38
Paoluzzi, L., Singh, A. S., Price, D. K., Danesi, R., Mathijssen, R. H. J., Verweij, J., Figg, W. D., & Sparreboom, A. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004267159 · Cited by 113
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38
Singh, A. S., Paoluzzi, L., Price, D. K., Danesi, R., Mathijssen, R. H. J., Verweij, J., Figg, W. D., & Sparreboom, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.2072 · Cited by 90
The APOE locus and the pharmacogenetics of lipid response
Ordovás, J. M., & Mooser, V. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200204000-00001 · Cited by 83
O’Neill, F. H., Patel, D., Knight, B. L., Neuwirth, C. K. Y., Bourbon, M., Soutar, A. K., Taylor, G. W., Thompson, G. R., & Naoumova, R. P. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.5.832 · Cited by 69
Roukos, D. H., Agnanti, N., Paraskevaidis, E. A., & Kappas, A. M. (2002) · Annals of Surgical Oncology · doi:10.1007/bf02574510 · Cited by 67
The Distribution of Sales Revenues from Pharmaceutical Innovation
Grabowski, H. G., & Vernon, J. (2000) · PharmacoEconomics · doi:10.2165/00019053-200018001-00005 · Cited by 66
Chasing Mutations in the Epidermal Growth Factor in Lung Cancer
Dowell, J. E., & Minna, J. D. (2005) · New England Journal of Medicine · doi:10.1056/nejme058033 · Cited by 32
Cited by
Meta-analysis of individual participant data: rationale, conduct, and reporting
Riley, R. D., Lambert, P. C., & Abo-Zaid, G. (2010) · BMJ · doi:10.1136/bmj.c221 · Cited by 1,701
Kapur, S., Phillips, A. G., & Insel, T. R. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.105 · Cited by 980
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research
Riley, R. D., Hayden, J. A., Steyerberg, E. W., Moons, K. G. M., Abrams, K., Kyzas, P. A., Malats, N., Briggs, A., Schroter, S., Altman, D. G., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001380 · Cited by 823
The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?
Lillie, E. O., Patay, B., Diamant, J., Issell, B., Topol, E. J., & Schork, N. J. (2011) · Personalized Medicine · doi:10.2217/pme.11.7 · Cited by 706
Metadata
- Authors
- Trusheim, M. R., Berndt, E. R., & Douglas, F. L.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-04
- Volume
- 6
- Issue
- 4
- Pages
- 287-293
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2015121141
- Cited by
- 509
- References
- 14
- FWCI
- 67.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.